S
Sight Sciences, Inc. (SGHT)
NMS – Real Time Price. Currency in USD
3.88
-0.12 (-3.00%)
At close: Mar 27, 2026, 4:00 PM EDT
3.92
+0.04 (1.03%)
After-hours: Mar 27, 2026, 5:28 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
3.88
-0.12 (-3.00%)
At close: Mar 27, 2026, 4:00 PM EDT
3.92
+0.04 (1.03%)
After-hours: Mar 27, 2026, 5:28 PM EDT
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
| Name | Position |
|---|---|
| Dr. David Badawi M.D. | Co-Founder, CTO & Director |
| Mr. Brenton Taylor | Executive Vice President of Operations and R&D |
| Mr. James Rodberg | CFO, Principal Financial Officer, Principal Accounting Officer & Treasurer |
| Mr. Jeremy B. Hayden J.D. | Chief Legal Officer & Corporate Secretary |
| Mr. Mark Papini | Senior Vice President of Interventional Glaucoma |
| Mr. Paul Badawi | Co-Founder, President, CEO & Director |
| Mr. Steve R. Tamayo Jr. | VP and Chief Ethics & Compliance Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-04 | 10-K | sght-20251231.htm |
| 2026-01-13 | 8-K | sght-20260113.htm |
| 2025-11-06 | 10-Q | sght-20250930.htm |
| 2025-10-17 | 8-K | sght-20251017.htm |
| 2025-09-30 | 8-K | sght-20250930.htm |
| 2025-08-27 | 8-K | sght-20250827.htm |
| 2025-08-07 | 8-K | sght-20250807.htm |
| 2025-06-05 | 8-K | d933197d8k.htm |
| 2025-05-30 | SD | sght-sd-conflictminerals.htm |
| 2025-05-08 | 8-K | sght-20250508.htm |
| Ms. Alison Perry Bauerlein |
| Chief Operating Officer |